NTLA Sep 2024 25.000 call
- GlobeNewswire
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
- Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidateCAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an abstract featuring redosing data from the Phase 1 study of NTLA-2001 has been selected for an oral present
- Zacks
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
- GlobeNewswire
Intellia Therapeutics Names Brian Goff to its Board of Directors
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. “We are very pleased to welcome Brian to our board of directors. Brian’s extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to
